Looking back to a meaningful weekend attending Parent Project Muscular Dystrophy 30th Annual Conference. PepGen appreciated the opportunity to attend this event with the #DMD community and participate in the “Research Row” panel. The PepGen talk is at the 32 minute mark: https://lnkd.in/eU4szt8W
PepGen
Biotechnology Research
Boston, Massachusetts 9,030 followers
Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies.
About us
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.
- Website
-
http://pepgen.com
External link for PepGen
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2018
- Specialties
- Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics
Locations
-
Primary
321 Harrison Ave
8th Floor
Boston, Massachusetts 02118, US
Employees at PepGen
Updates
-
Myotonic Dystrophy Foundation named July #MyotonicDystrophy #inMotion Awareness Month! PepGen hosted a lunch & learn highlighting recent data on the benefits of exercise for DM1 and a yoga class for staff. For more info on #MyotonicDystrophy #inMotion Awareness month visit: https://lnkd.in/ebFw-C-3
-
Today, PepGen announced data from its low-dose cohort of the ongoing CONNECT1 Phase 2 clinical trial in Duchenne muscular dystrophy. We will be hosting a conference call and webcast today at 4:30 pm ET to review the data. Click here for more information: https://lnkd.in/eStV77Nn
-
PepGen invites you to “Meet the #MyotonicDystrophy Drug Developers” webinar on Tuesday, August 2nd. Join PepGen and Dr. Johanna Hamel for a presentation on our DM1 clinical program, PGN-EDODM1. To register visit http://bit.ly/4bY4peQ
-
Meet Shaoxia Yu, Principal Scientist, here at PepGen. Specializing in our bioanalytics, biomarkers, and DMPK functions, Shaoxia's notable work has contributed towards advancing various stages of our drug development efforts. To learn more about our team, visit: https://bit.ly/48UJ8Ch
-
Ever wondered what sets our EDO platform apart? Hear from CMO Dr. Michelle Mellion, as she dives into the innovative approach powering our pipeline of potentially disease-modifying candidates. Discover how we're redefining possibilities in the neuromuscular and neurology space by potentially enhancing the delivery of oligonucleotides.
-
During the IDMC-14 International Myotonic Dystrophy Consortium Meeting in April, the advocacy group Stichting MD created a video titled 'What’s Happening Now,' featuring the DM1 community discussing what matters most to them about #MyotonicDystrophy. Check out the video below to listen to the insights of Jennifer Shoskes, PharmD, Associate Director, Clinical Development and others. #MyotonicDystrophy #Awareness #Advocacy https://lnkd.in/eF2pxjbW
MD: Whats happening now? - report from IDMC -14 Conference (2024)
https://www.youtube.com/
-
School may be out for summer, but #ProfessorPepGen is back with Lesson 2, “the Phases of Rare Disease clinical trials”. Check it out here! #patientadvocacy #clinicaltrials #biotech #patienteducation
-
We are looking forward to reporting preliminary data from the 5 mg/kg cohort of our CONNECT1 trial in DMD, expected mid-year. This will be followed with preliminary data from the higher 10 mg/kg dose cohort, further advancing our goal of transforming the treatment landscape for DMD. https://lnkd.in/ensfjvrF
-
We are excited to announce the expansion of our executive team with the appointments of Afsaneh Mohebbi, PhD as Senior Vice President, Portfolio and Program Management and Dave Borah, CFA as Senior Vice President, Investor Relations and Corporate Communications. Their experience will enhance PepGen’s expertise in critical areas of the organization, and we eagerly anticipate their contributions as we prepare for numerous key clinical milestones in the second half of this year. https://lnkd.in/eXBwvhfA